{"id":"W4392246441","doi":"10.1016/j.esmoop.2024.102358","title":"30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Genentech; Sierra Oncology; Daiichi Sankyo Europe; Servier; Eisai; Astellas Pharma; Basilea Pharmaceutica; PharmaMar; European Society for Medical Oncology; Pfizer; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Ipsen; Eisai Canada; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Blocking (statistics); Bifunctional; Medicine; Cancer research; Blocking antibody; Antibody; Immunology; Chemistry; Computer science","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007600316,0.0004924691,0.0007923462,0.0003187681,0.0003264283,0.0003301644,0.0002498611,0.0004730796,0.00376904],"category_scores_gemma":[0.0001835545,0.0002056404,0.000386663,0.0001412929,0.0005202797,0.0003299677,0.0002637481,0.001324322,0.0006818599],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003319042,"about_ca_system_score_gemma":0.0004181335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000904873,"about_ca_topic_score_gemma":0.001101421,"domain_scores_codex":[0.9998119,0.00006954475,0.000005691187,0.00003585272,0.0000224255,0.00005457797],"domain_scores_gemma":[0.9998016,0.00002948968,0.00001630413,0.00002156102,0.00001439474,0.0001166265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2021558,0.1189982,0.01067409,0.0004859232,0.0003879523,0.0006316141,0.0003653343,0.002414337,0.4360516,0.0005180426,0.006399193,0.2209179],"study_design_scores_gemma":[0.0317567,0.8690583,0.02180998,0.00001256044,0.0002356202,0.0005112431,0.00006839346,0.001829274,0.0639374,0.0002757279,0.0104822,0.00002260679],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957297,0.0005361263,0.0007108304,0.0001527352,0.00003446174,0.0008005174,0.0005078538,0.00007161438,0.001456119],"genre_scores_gemma":[0.9914858,0.0004345537,0.001348414,0.0002995995,0.0000535979,0.0006618826,0.0009662741,0.00002334146,0.004726643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00376904,"threshold_uncertainty_score":0.01260871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02055486266362737,"score_gpt":0.3161936157273622,"score_spread":0.2956387530637348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}